10-Q: PURE Bioscience Q1 Revenue Up, But Going Concern Looms

PURE Bioscience, Inc. reported increased net product sales and reduced operating loss for the first fiscal quarter ended October 31, 2025, yet continues to face substantial doubt regarding its ability to continue as a going concern.

Summary

• Net product sales increased by $152,000 to $707,000 for the three months ended October 31, 2025, compared to $555,000 in the prior year period.
• Gross profit rose to $450,000 from $325,000, with gross margin percentage improving to 64% from 58%.
• Net loss significantly improved to $(464,000) for the quarter, compared to $(689,000) in the same period last year.
• Operating loss decreased to $(379,000) from $(627,000) year-over-year.
• Cash and cash equivalents increased to $434,000 as of October 31, 2025, from $334,000 at July 31, 2025.
• The company continues to have a stockholders deficiency of $(5,546,000) as of October 31, 2025, and used $250,000 in operating activities during the quarter.
• A new $350,000 convertible note was issued to related parties on October 24, 2025, as part of a larger $2.0 million offering.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

Sentiment

Score: 4

Explanation: While the company showed improvements in revenue growth and reduced net loss, the persistent 'going concern' warning, significant stockholders deficiency, and heavy reliance on related-party convertible debt for financing indicate a precarious financial position. The positive operational trends are overshadowed by fundamental liquidity challenges and the need for continuous external funding.

Positives

• Net product sales increased by $152,000, reaching $707,000 for the quarter ended October 31, 2025, compared to $555,000 in the prior year.
• Gross margin percentage improved to 64% from 58% year-over-year, primarily due to the sale of higher packaging configurations.
• Net loss decreased significantly to $(464,000) from $(689,000) in the comparable prior year period.
• Operating loss improved to $(379,000) from $(627,000) in the prior year.
• Net cash used in operating activities decreased to $(250,000) from $(503,000) in the prior year period.
• Cash and cash equivalents increased by $100,000 to $509,000 (including restricted cash) at October 31, 2025, from $409,000 at July 31, 2025.
• Selling, general and administrative expenses decreased by $138,000 to $743,000, primarily due to reduced board fees, personnel costs, and facilities expenses.
• The reserve for inventory obsolescence decreased to $147,000 at October 31, 2025, from $212,000 at July 31, 2025.

Negatives

• The company has a history of recurring losses and a stockholders deficiency of $(5,546,000) as of October 31, 2025.
• A net loss of $(464,000) was recorded for the three months ended October 31, 2025.
• The company used $250,000 in cash for operating activities during the quarter.
• Total current liabilities significantly increased to $3,159,000 from $938,000, primarily due to $2,104,000 in current convertible notes payable to related parties.
• Interest expense increased to $94,000 from $62,000 in the prior year period due to accrued interest on convertible notes.
• A significant portion of net product sales (43%) and accounts receivable (42%) are concentrated with one individual customer, posing a concentration risk.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.

Risks

• **Going Concern**: The company has a history of recurring losses, a cumulative net loss of $139,500,000, and a stockholders deficiency of $5,546,000, raising substantial doubt about its ability to continue as a going concern.
• **Liquidity and Capital Requirements**: Existing cash resources are insufficient to meet anticipated needs over the next twelve months, requiring additional capital that may not be available on acceptable terms or at all.
• **Dilution Risk**: Raising additional funds through equity securities would likely result in substantial dilution to existing stockholders.
• **Debt Financing Restrictions**: Incurring debt financing may involve significant cash payment obligations, covenants, and specific financial ratios that could restrict business operations.
• **Relinquishing IP Rights**: Contracts or license arrangements to raise funds may require the company to relinquish rights to its products or technology.
• **Operational Delays/Cessation**: Insufficient funds may lead to delays or scaling back of marketing, distribution, and commercialization activities, or cessation of operations altogether.
• **Customer Concentration**: One individual customer accounted for 43% of net product sales for the three months ended October 31, 2025, and two customers comprised 42% and 10% of total accounts receivable, indicating significant reliance on a few customers.
• **Vendor Concentration**: Two vendors accounted for 34% and 14% of purchases, and one vendor accounted for 19% of accounts payable, indicating potential supply chain and payment risks.
• **Fluctuations in Operating Results**: Future results are subject to significant fluctuations due to buying patterns, product mix, component costs, inability to meet demand, R&D/regulatory milestones, unforeseen expenses, and manufacturing/supply issues.

Future Outlook

The company's future capital requirements are dependent on factors such as product acceptance and demand, success in sales and regulatory approvals, costs of product development, and investment in new technologies. It expects to continue funding operations through equity and debt offerings until positive cash flow is achieved, acknowledging potential dilution for stockholders or restrictive debt covenants.

Management Comments

• "We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control."
• "Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC."
• "We see significant market opportunities for our safe and effective SDC-based solutions, particularly in the food industry."
• "Our goal is to establish a sustainable company by commercializing SDC-based products developed through our proprietary technology platform."
• "We aim to deliver leading antimicrobial solutions that tackle food safety risks across the entire food industry supply chain."
• "We plan to leverage our technology platform through licensing and distribution collaborations to create new products and explore additional markets, aiming to generate multiple revenue streams."
• "We believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance."
• "As of the date of this filing, we are not aware of any trends in these factors or events or conditions that we believe are reasonably likely to impact our results of operations in the future."

Industry Context

PURE Bioscience operates in the antimicrobial solutions market, specifically targeting the food industry with its SDC-based products. The company's focus on expanding its distribution network and seeking international regulatory approvals aligns with a strategy to capture market share in a sector driven by increasing food safety regulations and consumer demand for effective, non-toxic sanitization. The continued reliance on related-party financing and the going concern warning suggest challenges in attracting broader institutional investment, potentially due to the competitive landscape or the company's stage of commercialization.

Related Party Transactions

• Convertible notes payable to related parties totaled $5,677,000 as of October 31, 2025.
• Tom Y. Lee, a Board member, invested $1,000,000 in the 2023 Private Placement, $1,785,000 in the 2024 Private Placement, $2,000,000 in the 2025 Private Placement, and $350,000 in the 2026 Private Placement. Ivan Chen, also a Board member, invested $15,000 in the 2023 Private Placement.
• Board fees due to officers and directors were $250,400 as of October 31, 2025, up from $185,700 at October 31, 2024.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution if additional equity financing is pursued. Existing stockholders face substantial doubt about the company's ability to continue as a going concern, which could impact share value.
• **Creditors (Convertible Note Holders)**: Related parties hold significant convertible debt, indicating their continued support but also exposure to the company's financial health. Conversion terms could impact their future equity stake.
• **Employees/Officers/Directors/Consultants**: Granted 3,395,000 stock options during the quarter, indicating ongoing incentive programs, but the going concern risk could affect job security and the value of equity awards.
• **Customers**: Increased sales suggest continued demand for SDC-based products, particularly PURE Hard Surface. However, the company's liquidity issues could pose a risk to product supply and long-term support.
• **Suppliers**: Increased accounts payable and reliance on a few key vendors suggest potential risks if the company's liquidity issues worsen.

Next Steps

• Continue growing and supporting the distribution network.
• Partner with third parties for international regulatory approvals for SDC-based products.
• Develop additional proprietary products and applications.
• Protect and enhance intellectual property.
• Seek additional equity and debt financing to fund operations until positive cash flow is achieved.
• Evaluate the provisions of ASU 2024-03 regarding disaggregation of income statement expenses.

Key Dates

Recommendation

Despite some operational improvements like increased revenue and reduced net loss, the company's fundamental financial health remains highly precarious. The explicit 'substantial doubt about its ability to continue as a going concern' from both management and its independent auditors is a critical red flag. The significant and growing stockholders' deficiency, coupled with heavy reliance on related-party convertible debt for ongoing operations, indicates a lack of sustainable funding. While sales are up, the concentration risk with a single major customer is concerning. The need for continuous external financing, with the explicit risk of substantial dilution or restrictive debt covenants, makes the stock a high-risk investment. A seasoned investor would likely view the going concern warning and the company's persistent negative equity as overwhelming factors, suggesting a 'sell' recommendation due to the high probability of further value erosion or even business failure without significant, non-dilutive capital infusion.

Keywords

PURE Bioscience, SDC, Silver Dihydrogen Citrate, Antimicrobial, Food Safety, PURE Hard Surface, PURE Control, SEC Filing, 10-Q, Quarterly Report, Financial Results, Going Concern, Convertible Notes, Biotechnology, Disinfectant, Sanitizer